Pfizer prunes three drugs from its pipeline; Astellas in-licenses ear drug
• Pfizer’s latest pipeline update comes with a notice of three midnight program executions. The pharma giant has pruned three drugs from its substantial pipeline, according to the update. The most advanced is a Phase II diabetes program for PF-06291874; followed by the early stage cardio drug PF-06815345 (hyperlipidemia) as well as the neuro drug PF-06412562, also in Phase I. None of these were high profile projects, none of the terminations were explained.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.